ArticleAmerican journal of translational research2025
Effects of neoadjuvant endocrine therapy on surgical prognosis and survival period in patients with high-risk localized prostate cancer.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the impact of Neoadjuvant Hormonal Therapy (NHT) on surgical prognosis and survival in patients with high-risk localized prostate cancer.
methodsA retrospective analysis was conducted on 371 high-risk prostate cancer patients who were treated at Baoji Central Hospital and Norinco General Hospital from January 2017 to January 2020. The patients were randomly divided into a training set of 286 cases (134 in the non-NHT group and 151 in the NHT group) and a validation set of 86 cases (42 in the non-NHT group and 44 in the NHT group). All patients underwent radical prostatectomy combined with pelvic lymph node dissection (RP+PLND). The baseline characteristics of the training and validation sets were collected. Surgical efficacy indicators (positive surgical margin rate, operative time, blood loss, etc.), 5-year overall survival (OS), metastasis-free survival (MFS), and biochemical recurrence-free survival (BRFS) were compared between the non-NHT and NHT groups in the training set. Independent risk factors for mortality were identified through univariate and multivariate analyses.
resultsThere were no significant differences in the baseline characteristics between the non-NHT and NHT groups in both the validation and training sets. In the training set, the NHT group demonstrated significantly better outcomes than the non-NHT group in terms of positive surgical margin rate (14.57% vs. 39.55%, P < 0.001), intraoperative blood loss (428.64±45.31 ml vs. 494.98±62.36 ml, P < 0.001), and operative time (143.00 min vs. 148.00 min, P < 0.001). The 5-year OS, MFS, and BRFS rates in the NHT group were 82.12% (124/151), 66.23% (100/151), and 40.02% (71/151), respectively, which were significantly higher than 55.97% (75/134), 44.03% (59/134), and 27.61% (37/134) in the non-NHT group (P < 0.001 for all). Multivariate analysis identified non-NHT treatment (OR = 7.528, P < 0.001), open surgery (OR = 4.581, P < 0.001), high clinical stage, high postoperative Gleason score, and high preoperative Prostate-Specific Antigen (PSA) as independent risk factors for mortality. Robotic-assisted surgery significantly reduced the incidence of long-term complications such as urethral stricture and bladder neck contracture compared with open surgery (P < 0.05 for all).
conclusionPreoperative NHT can improve surgical efficacy and long-term survival in patients with high-risk prostate cancer without increasing perioperative risks. Robotic-assisted surgery reduces long-term complications. NHT and preoperative PSA can serve as strong predictive indicators for the Nomogram model, providing references for individualized treatment. Further exploration of the optimal course of NHT and precision stratification guided by molecular markers is needed in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.